A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib or Placebo in Combination With Transarterial Grant uri icon

date/time interval

  • May 19, 2009 - December 10, 2013

total award amount

  • 82342.38

direct costs

  • 65873.90

sponsor award ID

  • 12918

local award ID

  • 00073202